Shop by goal
Popular compounds
Research resources
Recently viewed
Tirzepatide: A Research Guide to the Dual GLP-1 / GIP Agonist
Short answer: tirzepatide (LY3298176) is a 39-amino-acid synthetic peptide developed by Eli Lilly, the first dual agonist in its class - it simultaneously activates both the GLP-1 and GIP receptors. It is FDA-approved as Mounjaro (type-2 diabetes) and Zepbound (chronic weight management), with the head-to-head SURMOUNT-5 trial showing a greater mean weight reduction over 72 weeks than once-weekly semaglutide. New-U catalogues research-grade tirzepatide as Tirzepatide - lyophilised reference peptide, sealed vials, per-batch CoA, research use only.
Tirzepatide is the single most-searched peptide on the internet in 2026, with roughly 1 million monthly Google queries in the United States alone - nearly double the next compound in the category. That demand sits across two distinct populations: clinicians prescribing the approved branded product (Mounjaro, Zepbound), and the research community studying the underlying 39-amino-acid molecule. This guide is for the latter. It explains the mechanism, summarises the pivotal Phase 3 evidence (SURPASS, SURMOUNT, SURMOUNT-5), and frames what tirzepatide looks like as a research reference compound - catalogued on our site as Tirzepatide. For the broader GLP-1 class explainer see Is Ozempic a Peptide?; for the side-by-side single-vs-dual mechanism comparison see Semaglutide vs Tirzepatide.
Plain-English summary. Tirzepatide is an approved medicine in the United States, the United Kingdom and many other jurisdictions when supplied through licensed channels as Mounjaro or Zepbound. Research-grade tirzepatide, sold as a lyophilised reference peptide for laboratory use, is a separate non-medicine category. New-U sells only the research reagent - not the medicine - with no human-use claims, no dosing guidance and no therapeutic protocol. This page is general information, not legal or medical advice.
What tirzepatide actually is
Tirzepatide, developmental code LY3298176 , is a 39-amino-acid synthetic peptide modelled on the native GIP backbone. A C20 fatty acid is attached via a γ-Glu-2xOEG linker at Lys20; that lipid tail drives reversible albumin binding , which extends the half-life to roughly 5 days . The long half-life is what enables once-weekly subcutaneous administration in the licensed product. Structurally, tirzepatide is not a GLP-1 analogue with a GIP feature bolted on - it is a GIP-derived sequence engineered to acquire potent GLP-1 receptor binding while retaining native GIP activity.
That dual-agonist property is the entire point. GLP-1 and GIP are the two principal incretins - gut-derived hormones released after a meal that potentiate glucose-dependent insulin secretion. Native GIP loses activity in type-2 diabetes; restoring GIP-receptor signalling alongside GLP-1 activation is hypothesised to be the mechanistic reason tirzepatide produces larger metabolic effects than GLP-1 mono-agonists. The full mechanism is reviewed in the StatPearls tirzepatide chapter.
Mechanism of action, in plain English
Tirzepatide does four things simultaneously:
The dual GIP arm adds an additional set of effects on adipose tissue glucose handling and energy expenditure. The net result, as documented in the Phase 3 programme, is a larger mean body-weight reduction than any approved GLP-1 mono-agonist had previously demonstrated.
The Phase 3 evidence: SURPASS and SURMOUNT
Tirzepatide’s approval rests on two trial programmes:
SURPASS (type-2 diabetes, n > 13,000 across SURPASS-1 through SURPASS-6). At the 15 mg weekly dose, tirzepatide produced HbA1c reductions of ~2.1–2.4% from baseline, larger than insulin glargine and larger than semaglutide 1.0 mg in the SURPASS-2 head-to-head.
SURMOUNT (chronic weight management). SURMOUNT-1 reported mean weight reduction of ~20.9% at the 15 mg dose over 72 weeks in adults with obesity without diabetes, with a placebo-corrected difference of around 17.8 percentage points - the largest effect ever recorded for a single pharmacological agent in an obesity trial at the time of publication.
The head-to-head SURMOUNT-5 trial (NEJM, 2025) compared tirzepatide and semaglutide directly over 72 weeks. Tirzepatide produced a significantly greater mean reduction in body weight than semaglutide, with the magnitude of the difference roughly mirroring what the cross-trial comparisons had already suggested.
Tirzepatide vs semaglutide vs retatrutide
The incretin landscape now spans three receptor profiles and three approval stages:
Each step up the agonist count adds an additional metabolic pathway: semaglutide acts on GLP-1 alone; tirzepatide adds GIP-receptor signalling; retatrutide adds glucagon-receptor agonism, which contributes hepatic thermogenesis and an additional energy-expenditure arm. For the regulatory framing of each one in the UK specifically, see Where to Buy Retatrutide in the UK.
Pharmacokinetics: why once-weekly works
Native GLP-1 has a circulating half-life of roughly 2 minutes - it is degraded almost instantly by DPP-4. Tirzepatide gets to ~5 days by a combination of three engineering choices: (1) the C20 fatty acid for albumin binding, (2) Aib substitutions at residues 2 and 13 that block DPP-4 cleavage, and (3) the γ-Glu-2xOEG linker that positions the fatty acid for optimal albumin affinity. Steady-state plasma concentration is reached after roughly 4 weeks of weekly dosing.
Tirzepatide as a research compound
On the New-U catalogue, the research-grade reference peptide is listed as Tirzepatide . Same 39-amino-acid sequence, same dual GLP-1/GIP receptor mechanism, same molecule that Eli Lilly studies as LY3298176, supplied here as a research compound within our incretin reference range. The product is a sealed glass vial of lyophilised peptide for laboratory use only.
The reason for the research-compound posture is the same reason it matters everywhere else in this catalogue: a peptide marketed for human use is a medicine, and selling an unapproved medicine is the line both the FDA and MHRA actually enforce. A lyophilised reference peptide labelled research use only, not for human consumption sits in a separate, lawful category. See Are Peptides Legal? for the US framing and Are Peptides Legal in the UK? for the UK.
How to verify tirzepatide purity
For a 39-amino-acid peptide with a fatty acid tail, the purity questions are:
Our walkthrough of every line item is in How to Read a Certificate of Analysis.
Red flags on tirzepatide listings
The same scam patterns appear across the entire GLP-1 cluster. Walk away from any tirzepatide listing that:
Storage & handling of lyophilised tirzepatide
Lyophilised tirzepatide is robust at standard freezer temperatures but should be handled like the long-chain modified peptide it is. Keep sealed vials at −20°C for long-term storage. Allow vials to reach room temperature before opening so condensation does not enter the vial. Reconstitute only the volume needed; once reconstituted, store at 2–8°C and protect from light. Our full handling reference is in How to Store Peptides.
Frequently Asked Questions
What is tirzepatide? A 39-amino-acid synthetic peptide developed by Eli Lilly (developmental code LY3298176). It is a dual agonist of the GLP-1 and GIP receptors, marketed as Mounjaro for type-2 diabetes and Zepbound for chronic weight management.
How is tirzepatide different from semaglutide? Semaglutide is a single GLP-1 agonist. Tirzepatide adds GIP-receptor agonism - the “dual” in dual incretin agonist. In SURMOUNT-5 (NEJM, 2025) tirzepatide produced a significantly greater mean weight reduction than semaglutide over 72 weeks.
What is tirzepatide’s half-life? Approximately 5 days, enabling once-weekly subcutaneous dosing. The long half-life comes from a C20 fatty acid moiety that drives reversible albumin binding.
Is tirzepatide a research compound on this site? Yes. New-U catalogues research-grade tirzepatide as Tirzepatide, lyophilised reference peptide with a per-batch Certificate of Analysis. Sold research use only, not for human consumption.
How do I verify tirzepatide purity? Demand a per-batch CoA showing >99% HPLC purity and a mass-spec identity match to the calculated monoisotopic mass, from a named third-party lab. See how to read a CoA.
Related Reading
Primary sources & further reading
External links are provided for research reference only; New-U is not affiliated with the cited organisations and links carry no endorsement either way. Mounjaro and Zepbound are trade names of Eli Lilly and Company; New-U sells research-grade reference peptide only, not the licensed medicine.
From the Lab - Peptides on LinkedIn & Facebook
Lab-Verified Research Tirzepatide
New-U Research Compounds catalogues tirzepatide as Tirzepatide - sealed 10-vial packs of lyophilised reference peptide, independently verified by Janoshik and Freedom Diagnostics for >99% HPLC purity, with a per-batch Certificate of Analysis. Tracked worldwide delivery. Research use only - not for human consumption.
Research-grade · >99% HPLC purity · COA per lot
Buy Tirzepatide from New-U Research Compounds
Lab-verified by Janoshik Analytical (RP-HPLC + ESI-MS), sealed vials, discreet tracked worldwide shipping. For laboratory research use only — not for human consumption.
Premium research peptides at >99% HPLC-verified purity, third-party tested by Janoshik Analytical with a Certificate of Analysis on every lot. Shipped lab-direct, discreet and cold-chain, worldwide. For laboratory research use only.
Shop
Learn
Company
Support
Ways to Pay
Shop by Compound
Shop by Goal
Ships worldwide
Research use only (RUO). All products are sold strictly for laboratory and research purposes — not for human or veterinary consumption. Purchasers must be 21 or older.
All rights reserved. Copyright of New-U held with Hilxera Distribution Services LLC 2026.
Website & business operated by Hilxera Distribution Services LLC. Registered in Wyoming, ID: 2026-001928701.
© 2026 New-U Research Compounds · new-u.io · @new.u.io